• ICG001: Deciphering Wnt/β-Catenin-Driven EMT and Fibrosis Me

  2026-06-03

  Discover how ICG001, a potent Wnt/β-catenin pathway inhibitor, enables advanced dissection of epithelial–mesenchymal transition (EMT) and fibrosis mechanisms. This article uniquely integrates recent mechanistic insights and protocol guidance for researchers seeking depth beyond standard workflows.

• Quercetin Enhances Angiogenesis and BSCB Integrity After SCI

  2026-06-03

  Liu et al. reveal that quercetin promotes angiogenesis and preserves the blood-spinal cord barrier (BSCB) following spinal cord injury by activating the PI3K/Akt signaling pathway. These advances illuminate new strategies for supporting neural repair and vascular remodeling in SCI models.

• Fenofibrate Activates PPARα-YAP Pathway to Enlarge Aging Mou

  2026-06-02

  This study demonstrates that Fenofibrate, a PPARα agonist, induces liver enlargement in both adult and aging mice through activation of the PPARα-YAP signaling pathway. The effects occur independently of age, providing new insights into liver physiology and the safe use of PPARα agonists in elderly research models.

• HBTU in Peptide Synthesis: Workflow, Innovation, and Trouble

  2026-06-02

  HBTU stands out as a racemization-resistant coupling reagent, enabling high-yield peptide synthesis with rapid workflows and exceptional reliability. Explore detailed protocols, real-world troubleshooting, and advanced applications that leverage HBTU’s unique chemistry for next-generation peptide therapeutics.

• O-GlcNAcylation Drives Wnt-Mediated Bone Anabolism via Glyco

  2026-06-01

  This study uncovers how O-GlcNAcylation acts as a metabolic switch in Wnt-stimulated bone formation, revealing its necessity for osteoblastogenesis and fracture healing. Mechanistic insights into glycolytic regulation offer new avenues for dissecting bone anabolic pathways and metabolic interventions.

• Deracoxib and Piroxicam Cytotoxicity in Canine Osteosarcoma

  2026-06-01

  This study evaluates the in vitro cytotoxic effects of deracoxib and piroxicam on canine osteosarcoma cell lines, demonstrating that deracoxib achieves more potent inhibition of cell viability than piroxicam, with minimal toxicity to fibroblasts. The findings refine our understanding of NSAIDs as potential antiproliferative agents in bone tumor models and inform future research in osteoclast-mediated bone resorption inhibition.

• Applied Use of α-Linolenic Acid in Lipid Metabolism Research

  2026-05-31

  Harnessing α-Linolenic Acid (ALA) from APExBIO empowers precision in dissecting lipid metabolism, cardiovascular function, and immune modulation across cellular and animal models. This guide offers actionable protocols, troubleshooting insights, and workflow enhancements to maximize research reproducibility and translational relevance.

• 2-NBDG for Quantitative Glucose Uptake: Advanced Workflows &

  2026-05-30

  2-NBDG enables high-sensitivity, real-time quantification of cellular glucose uptake with unparalleled workflow flexibility. Integrating this fluorescent glucose analog streamlines metabolic assays across disease models, delivering reproducible results even in challenging experimental contexts.

• Safe DNA Gel Stain: Advanced Nucleic Acid Detection & Workfl

  2026-05-29

  Safe DNA Gel Stain empowers molecular biology labs with high-sensitivity DNA and RNA visualization, minimizing mutagenic risks and supporting improved cloning outcomes. This guide unpacks applied protocols, troubleshooting, and the science behind safer nucleic acid detection with APExBIO's innovative stain.

• Grazoprevir/Elbasvir Therapy: Advances in HCV Genotype 1/4 T

  2026-05-29

  The reference review by Vallet-Pichard and Pol systematically evaluates the clinical efficacy, safety, and mechanistic rationale of the fixed-dose combination of Grazoprevir (MK-5172 hydrate) and Elbasvir for hepatitis C virus (HCV) infection. This combination represents a pivotal advance in direct-acting antiviral (DAA) regimens, particularly for HCV genotypes 1 and 4, with implications for challenging patient populations such as those with HIV/HCV coinfection or chronic kidney disease.

• MMP7 Drives EMT and Liver Fibrosis via E-cadherin/β-catenin

  2026-05-28

  This study establishes matrix metalloproteinase 7 (MMP7) as a key mediator of epithelial–mesenchymal transition (EMT) and liver fibrosis in biliary atresia (BA) through cleavage of E-cadherin and activation of β-catenin signaling. The findings highlight MMP7 as a promising therapeutic target and provide mechanistic insight into rapid fibrotic progression in BA.

• Enhancing Pancreatic Cancer Cell Death via Caspase-8/c-FLIPL

  2026-05-28

  A recent study demonstrates that pharmacological targeting of the caspase-8/c-FLIPL heterodimer, combined with MCL1 inhibition, enhances apoptotic cell death in pancreatic cancer cells by promoting complex II assembly. This combinatorial approach offers mechanistic insight into overcoming apoptosis resistance in cancer and informs experimental strategies for researchers investigating cell death pathways.

• Adap2 Drives Cardiomyocyte Hypertrophy via Surface β1-Integr

  2026-05-27

  This study elucidates the previously uncharacterized role of Adap2 (ArfGAP with dual pleckstrin homology domains 2) in promoting hypertrophy of cultured neonatal cardiomyocytes. Through adenoviral-mediated overexpression and membrane protein analysis, the research demonstrates that Adap2 enhances cell surface β1-integrin accumulation and cell size, highlighting a distinct molecular mechanism from its homolog Adap1.

• N4-Acetylcytidine in RNA Metabolism: Mechanisms and Assay St

  2026-05-27

  Explore how N4-Acetylcytidine advances RNA epigenetics research with new structural insights into nucleotide processing. This in-depth article reveals unique mechanistic findings and assay considerations for acetylated cytidine, setting it apart from standard workflows.

• SAR131675: Selective VEGFR-3 Inhibitor for Lymphangiogenesis

  2026-05-26

  SAR131675 is a potent and selective VEGFR-3 inhibitor, acting as an ATP-competitive compound with nanomolar efficacy. It demonstrates high specificity for VEGFR-3, robust anti-lymphangiogenic and anti-angiogenic activity, and is a validated tool for dissecting VEGFC-driven pathways in fibrosis and tumor models.

15709 records 1/1048 page Next 12345 下5页 Last page